摘要
目的:比较重组组织型纤溶酶原激活剂(rt-PA)静脉溶栓治疗心源性脑梗死(CE)和非心源性脑梗死(NCE)患者的疗效。方法:2018年8月-2019年7月收治急性脑梗死患者64例,根据脑梗死类型不同,分为CE组、NCE组,各32例,均接受rt-PA静脉溶栓治疗,比较疗效。结果:比较两组治疗后2 h、24 h、7 d NIHSS评分,差异无统计学意义(P>0.05);两组治疗后7 d、90 d mRS评分比较,差异无统计学意义(P>0.05);治疗及随访期间,CE组不良事件发生率高于NCE组,差异有统计学意义(P<0.05)。结论:CE、NCE患者接受rt-PA静脉溶栓治疗均能够取得较好的疗效及预后,但CE患者不良事件风险较高,应提高警惕。
Objective:To compare the efficacy of intravenous thrombolysis with rt-PA in the treatment of CE and NCE.Methods:64 patients with acute cerebral infarction were selected from August 2018 to July 2019,according to the different types of cerebral infarction,the patients were divided into the CE group and the NCE group with 32 cases in each group.Results:There was no significant difference in NIHSS scores between the two groups at 2,24 hours and 7 days after treatment(P>0.05).There was no significant difference in mRS score between the two groups at 7 and 90 days after treatment(P>0.05).During treatment and follow-up,the incidence of adverse events in the CE group was higher than that in the NCE group,the differences were statistically significant(P<0.05).Conclusion:Patients with CE and nce can get better curative effect and prognosis after rt-PA intravenous thrombolysis,but the risk of adverse events in CE patients is higher,so we should be alert.
作者
李燕玲
Li Yanling(Department of Neurology,the First People's Hospital of Qujing City,Yunnan Province,Yunnan Qujing 655000)
出处
《中国社区医师》
2020年第12期57-58,共2页
Chinese Community Doctors
关键词
脑梗死
静脉溶栓
心源性
Cerebral infarction
Intravenous thrombolysis
Cardiogenic
